USA Health Homepage

Navigation

Poosarla_T2

Teja Poosarla, M.D.

Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical OncologySpecialty: Cancer Care
Refer a Patient
Request an Appointment
Or call to make an appointment1 (251) 665-8000

Conditions Treated

  • Breast Cancer

Professional Memberships

  • American College of Physicians
  • American Society of Clinical Oncology (ASCO)
  • American Society of Hematology (ASH)
  • Society of Hematologic Oncology (SOHO)

Board Certifications

  • American Board of Internal Medicine
  • Certification in Medical Oncology and Hematology

Education

  • Medical School: University of South Alabama College of Medicine | Mobile, AL
  • Residency: Ochsner Clinic Foundation | New Orleans, LA
  • Fellowship (Hematology and Oncology): University of Mississippi | Jackson, MS

Languages

  • English

Locations

Clinical Trials

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerStatus: open

16-207 - [923977-5] Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Treatment for Breast Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, AL 36604
Learn More
(251) 445-9834
Pembrolizumab in Treating Patients With Triple-Negative Breast CancerStatus: open

18-002 - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy - SWOG S1418 (BR0006)

Treatment for Breast Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, AL 36604
Learn More
(251) 445-9834
Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyStatus: open

15-196 - EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Treatment for Breast Cancer

Mitchell Cancer Institute
1660 SpringHill Avenue
Mobile, AL 36604
Learn More
(251) 445-9834
This link will open in a new tab or window.